Analysts Adjust Immunome's Price Target Amid Developments Guggenheim Securities reduced Immunome's price target from $35 to $25, reflecting stock dilution from a recent capital raise. However, advancements in its pipeline, including Phase 1 trials for IM-1021 and IND clearance for IM-3050, suggest potential growth. The company continues to focus on oncology innovations to drive future value.45